Data reported that TQ or the α7 nAChR agonist in combination with the PAM had a pivotal role in the treatment of AD, by reducing the neuroinflammation, and by activating the mesenchymal stem cells (MSCs). This evidence concerns the gene CHRNA7 and Alzheimer disease.